{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:34:46Z","timestamp":1793896486618,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05549-1","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:05:11Z","timestamp":1783537511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Leukemic architecture as a framework for risk stratification in NPM1-mutated acute myeloid leukemia"],"prefix":"10.1007","volume":"17","author":[{"given":"Francesco","family":"Tarantini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Anelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Zagaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Cumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Coccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Minervini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Tota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosa","family":"Conserva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immacolata","family":"Redavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crescenzio Francesco","family":"Minervini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Parciante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-6052","authenticated-orcid":false,"given":"Francesco","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"5549_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","volume":"352","author":"B Falini","year":"2005","unstructured":"Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254\u201366.","journal-title":"N Engl J Med"},{"key":"5549_CR2","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey EH, Amadori S, Appelbaum FR, B\u00fcchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood; 2010; pp. 453\u201374.","DOI":"10.1182\/blood-2009-07-235358"},{"key":"5549_CR3","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2005-06-2248","volume":"106","author":"S Schnittger","year":"2005","unstructured":"Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106:3733\u20139.","journal-title":"Blood"},{"key":"5549_CR4","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","volume":"107","author":"C Thiede","year":"2006","unstructured":"Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011\u201320.","journal-title":"Blood"},{"key":"5549_CR5","first-page":"12","volume":"17","author":"AS Mer","year":"2021","unstructured":"Mer AS, Heath EM, Madani Tonekaboni SA, Dogan-Artun N, Nair SK, Murison A, et al. Biological and therapeutic implications of a unique subtype of NPM1 mutated AML. Nat Commun. 2021;17:12.","journal-title":"Nat Commun"},{"key":"5549_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41375-024-02137-6","volume":"38","author":"JF Severens","year":"2024","unstructured":"Severens JF, van der Karakaslar EO, van den S\u00e1nchez-L\u00f3pez E, Halkes CJM, et al. Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses. Leukemia. 2024;38:751\u201361.","journal-title":"Leukemia"},{"key":"5549_CR7","first-page":"564","volume":"32","author":"I Singh","year":"2025","unstructured":"Singh I, Fernandez-Perez D, Sanchez PS, Rodriguez-Fraticelli AE. Pre-existing stem cell heterogeneity dictates clonal responses to the acquisition of leukemic driver mutations. Cell Stem. 2025;32:564\u2013e5806.","journal-title":"Cell Stem"},{"key":"5549_CR8","doi-asserted-by":"publisher","first-page":"10592","DOI":"10.1038\/s41467-025-66546-6","volume":"16","author":"H Lilljebj\u00f6rn","year":"2025","unstructured":"Lilljebj\u00f6rn H, Pe\u00f1a-Mart\u00ednez P, Thorsson H, Henningsson R, Rissler M, Landberg N, et al. The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes. Nat Commun. 2025;16:10592.","journal-title":"Nat Commun"},{"key":"5549_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1182\/blood.2024024310","volume":"144","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, et al. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML. Blood. 2024;144:714\u201328.","journal-title":"Blood"},{"key":"5549_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41408-022-00734-1","volume":"12","author":"M Di Duchmann","year":"2022","unstructured":"Duchmann M, Joudinaud R, Boudry A, Pasanisi J, Di Feo G, Kim R, et al. Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML. Blood Cancer J. 2022;12:136.","journal-title":"Blood Cancer J"},{"key":"5549_CR11","doi-asserted-by":"crossref","unstructured":"Drucker M, Lee D, Zhang X, Kain B, Bowman M, Nicolet D et al. Genotype-immunophenotype relationships in NPM1-mutant AML clonal evolution uncovered by single cell multiomic analysis. bioRxiv Prepr Serv Biol. 2024; https:\/\/pubmed.ncbi.nlm.nih.gov\/39605444\/. Accessed 17 Mar 2026.","DOI":"10.1101\/2024.11.11.623033"},{"key":"5549_CR12","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1038\/s41375-025-02745-w","volume":"39","author":"EO Karakaslar","year":"2025","unstructured":"Karakaslar EO, Argiro EM, Struckman NE, Shirali HZR, Severens JF, Honders MW, et al. Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution. Leukemia. 2025;39:2916\u201325.","journal-title":"Leukemia"},{"key":"5549_CR13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020;10:536\u201351.","journal-title":"Cancer Discov"},{"key":"5549_CR14","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1038\/s41375-019-0502-0","volume":"33","author":"LV Cappelli","year":"2019","unstructured":"Cappelli LV, Meggendorfer M, Dicker F, Jeromin S, Hutter S, Kern W, et al. DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern. Leukemia. 2019;33:2741\u20136.","journal-title":"Leukemia"},{"key":"5549_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature13038","volume":"506","author":"LI Shlush","year":"2014","unstructured":"Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328\u201333.","journal-title":"Nature"},{"key":"5549_CR16","doi-asserted-by":"publisher","first-page":"e3519","DOI":"10.1097\/MD.0000000000003519","volume":"95","author":"XQ Yuan","year":"2016","unstructured":"Yuan XQ, Peng L, Zeng WJ, Jiang BY, Li GC, Chen XP. DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients. Med (Baltim). 2016;95:e3519.","journal-title":"Med (Baltim)"},{"key":"5549_CR17","doi-asserted-by":"crossref","unstructured":"Cocciardi S, Saadati M, Wei\u00df N, Sp\u00e4th D, Kapp-Schwoerer S, Schneider I et al. Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML. HemaSphere. 2025.","DOI":"10.1002\/hem3.70060"},{"key":"5549_CR18","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2352-3026(23)00089-3","volume":"10","author":"H D\u00f6hner","year":"2023","unstructured":"D\u00f6hner H, Weber D, Krzykalla J, Fiedler W, K\u00fchn MWM, Schroeder T, et al. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09\u201309): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2023;10:e495\u2013509.","journal-title":"Lancet Haematol"},{"key":"5549_CR19","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/NEJMc1608739","volume":"375","author":"F Lemonnier","year":"2016","unstructured":"Lemonnier F, Inoue S, Mak TW. Genomic Classification in Acute Myeloid Leukemia. N Engl J Med. 2016;375:900.","journal-title":"N Engl J Med"},{"key":"5549_CR20","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1182\/blood.2019003339","volume":"135","author":"MF Bezerra","year":"2020","unstructured":"Bezerra MF, Lima AS, Piqu\u00e9-Borr\u00e0s MR, Silveira DR, Coelho-Silva JL, Pereira-Martins DA, et al. Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. Blood. 2020;135:870\u20135.","journal-title":"Blood"},{"key":"5549_CR21","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-S\u00e1nchez A, Villaverde Ramiro \u00c1, Str\u00e4ng E, Turki AT, Ab\u00e1igar M, Versluis J et al. Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study. Leukemia. 2026; https:\/\/pubmed.ncbi.nlm.nih.gov\/41535568\/. Accessed 17 Mar 2026.","DOI":"10.1038\/s41375-025-02851-9"},{"key":"5549_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1182\/blood.2018862383","volume":"134","author":"S Garg","year":"2019","unstructured":"Garg S, Reyes-Palomares A, He L, Bergeron A, Lavall\u00e9e VP, Lemieux S, et al. Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML. Blood. 2019;134:263\u201376.","journal-title":"Blood"},{"key":"5549_CR23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/ajh.25018","volume":"93","author":"EF Mason","year":"2018","unstructured":"Mason EF, Kuo FC, Hasserjian RP, Seegmiller AC, Pozdnyakova O. A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1\/2 mutations and improved outcome. Am J Hematol. 2018;93:504\u201310.","journal-title":"Am J Hematol"},{"key":"5549_CR24","first-page":"339","volume":"146","author":"W Walter","year":"2025","unstructured":"Walter W, Keppler S, Ecker V, Kern W, Haferlach T, Stengel A. Bi-allelic TET2 alterations are frequently found in NPM1 mutated AML and constitute a distinct subgroup with unfavorable prognosis. Blood Am Soc Hematol. 2025;146:339\u2013339.","journal-title":"Blood Am Soc Hematol"},{"key":"5549_CR25","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"5549_CR26","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","volume":"111","author":"U Bacher","year":"2008","unstructured":"Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters\u2013an analysis of 3082 patients. Blood. 2008;111:2527\u201337.","journal-title":"Blood"},{"key":"5549_CR27","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/bloodadvances.2017009019","volume":"1","author":"P Boddu","year":"2017","unstructured":"Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, et al. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv. 2017;1:1546\u201350.","journal-title":"Blood Adv"},{"key":"5549_CR28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/cancers17010131","volume":"17","author":"S Arora","year":"2025","unstructured":"Arora S, Jen WY, Yilmaz M, Deshmukh I, Senapati J, Loghavi S, et al. Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation. Cancer. 2025;17:131.","journal-title":"Cancer"},{"key":"5549_CR29","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"5549_CR30","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"5549_CR31","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1007\/s00277-025-06431-w","volume":"104","author":"T Wang","year":"2025","unstructured":"Wang T, Zhao L, Ma H. Impact of secondary-type mutations on the prognosis of AML patients with NPM1 mutation: a systematic review and meta-analysis. Ann Hematol. 2025;104:3103\u201315.","journal-title":"Ann Hematol"},{"key":"5549_CR32","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41375-026-02874-w","volume":"40","author":"R Mecklenbrauck","year":"2026","unstructured":"Mecklenbrauck R, Villaverde Ramiro A, Str\u00e4ng E, Gabdoulline R, Martinez Elicegui J, Sobas M, et al. Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia. Leukemia. 2026;40:622\u20139.","journal-title":"Leukemia"},{"key":"5549_CR33","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","volume":"35","author":"L Bullinger","year":"2017","unstructured":"Bullinger L, D\u00f6hner K, Dohner H. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. J Clin Oncol. 2017;35:934\u201346.","journal-title":"J Clin Oncol"},{"key":"5549_CR34","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/blood.2022018582","volume":"141","author":"L Angenendt","year":"2023","unstructured":"Angenendt L, R\u00f6llig C, Montesinos P, Ravandi F, Juliusson G, R\u00e9cher C, et al. Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification. Blood. 2023;141:433\u20135.","journal-title":"Blood"},{"key":"5549_CR35","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO-24-01715","volume":"43","author":"C Tregnago","year":"2025","unstructured":"Tregnago C, Benetton M, Ries RE, Peplinski JH, Alonzo TA, Stirewalt D, et al. Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration. J Clin Oncol. 2025;43:972\u201384.","journal-title":"J Clin Oncol"},{"key":"5549_CR36","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00277-024-05786-w","volume":"103","author":"Y Shi","year":"2024","unstructured":"Shi Y, Chen X, Jin H, Zhu L, Hong M, Zhu Y, et al. Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients. Ann Hematol. 2024;103:2323\u201335.","journal-title":"Ann Hematol"},{"key":"5549_CR37","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med. 2016;374:422\u201333.","journal-title":"N Engl J Med"},{"key":"5549_CR38","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.2025031480","volume":"147","author":"J Cloos","year":"2026","unstructured":"Cloos J, Valk PJM, Thiede C, D\u00f6hner K, Roboz GJ, Wood BL, et al. 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood. 2026;147:1147\u201367.","journal-title":"Blood"},{"key":"5549_CR39","doi-asserted-by":"crossref","unstructured":"L F, I S, M TW. Genomic Classification in Acute Myeloid Leukemia. N Engl J Med. 2016;375:900\u20131.","DOI":"10.1056\/NEJMc1608739"},{"key":"5549_CR40","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood.2023023096","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, et al. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 2024;143:1931\u20136.","journal-title":"Blood"},{"key":"5549_CR41","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1182\/bloodadvances.2018023432","volume":"2","author":"A H\u00f6llein","year":"2018","unstructured":"H\u00f6llein A, Meggendorfer M, Dicker F, Jeromin S, Nadarajah N, Kern W, et al. NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. Blood Adv. 2018;2:3118\u201325.","journal-title":"Blood Adv"},{"key":"5549_CR42","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"5549_CR43","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:2169\u201373.","journal-title":"Blood"},{"key":"5549_CR44","doi-asserted-by":"crossref","unstructured":"Thakur RK, Wang ES. The promise of menin inhibitors: from approval to triplet regimens. Hematol Am Soc Hematol Educ Progr. Hematology Am Soc Hematol Educ Program; 2025. pp. 599\u2013606.","DOI":"10.1182\/hematology.2025000755"},{"key":"5549_CR45","doi-asserted-by":"publisher","first-page":"7118","DOI":"10.1016\/j.cell.2025.10.010","volume":"188","author":"GK Datar","year":"2025","unstructured":"Datar GK, Khabusheva E, Anand A, Beale J, Sadek M, Chen CW, et al. Disparate leukemia mutations converge on nuclear phase-separated condensates. Cell. 2025;188:7118\u2013e713621.","journal-title":"Cell"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05549-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:17:10Z","timestamp":1790896630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05549-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5549"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05549-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1398"}}